**Professor John M.S. Bartlett BSc, PhD, FRCPath**
Director, Transformative Pathology, Ontario Institute for Cancer Research

***Work Experience:***

| | |
|---|---|
| *1982-1986* | PhD student & Post Doctoral Research Fellow (Funded by J. Reprod. Biol. Fellowship), MRC Reproductive Biology Unit, Edinburgh |
| 1986-1989 | Post Doctoral Research Fellow & Research Scientist: Max Planck Dept Reproductive Medicine, Steinfurter Strasse 107, Muenster. Germany |
| 1990-1992 | Post Doctoral Research Fellow: ICRF Medical Oncology Unit, Western General Hospital Edinburgh EH4 2XU. |
| 1992-1997 | Lecturer University Dept Surgery. Glasgow University |
| 1998-2004 | Senior Lecturer University Dept Surgery, Glasgow University, G31 2ER |
| 2004-2006 | Reader University Dept Surgery,Glasgow University |
| 2006-2008 | Reader in Molecular Pathology, The University of Edinburgh |
| 2008-2011 | Professor of Molecular Pathology, The University of Edinburgh |
| 2011- | Honorary Professor, The University of Edinburgh |
| 2011- | Affiliate Scientist, University Health Network, Toronto |
| 2011- | Professor (Status-Only), Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto |
| 2011- | Director, Transformative Pathology, OICR, Toronto |

***Academic and Training Background:***

| | |
|---|---|
| 1979-1982 | BSc. Honours Biochemistry 2.1, University of Bath |
| 1982-1986 | PhD, Reproductive Endocrinology, University of Edinburgh (1982-1986) |
| 1985-1986 | Postdoctorate, Reproductive Endocrinology, Medical Research Council (MRC), Reproductive Biology Unit |
| 1986-1988 | Postdoctorate, Reproductive Endocrinology, Max Planck Institute, Department of Reproductive Medicine |
| 2008- | FRCPath, The Royal College of Pathologists |

***Selected Accomplishments and Honours:***

I currently serve on a number of trial management groups and steering committees either as the principal investigator for translational science or as part of the group responsible for clinical trial design. At present I am a member of the following committees:

1. **TEAM (Tamoxifen versus Exemestane as Adjuvant Chemotherapy) Trial:**
   - UK Steering committee Member, International Steering committee Member, Translational Science committee (TRANS-TEAM) PI and Chair
2. **TRANS-TACT (Taxotere as adjuvant Chemotherapy Trial) Translational science committee**
3. **TACT-2** ***(Trial of Adjuvant Chemotherapy 2)****:*
   - Steering committee Member and Member of Trial Management Group
4. **MRC-SUPREMO Trial (Randomised trial of chest wall radiotherapy)**
   - Member of International Trial Management Group and Trial Steering Committee.
   - Translational Science committee (TRANS-SUPREMO) Chair
5. **REACT (Randomised EuropeAn Celecoxib Trial)**
   - Steering Committee member National and International Steering Committee
6. **NEAT SCIENCE/BR9601**
   - Steering committee member
7. **NEO-EXCEL Neoadjuvant trial of pre-operative exemestane or letrozole +/- celecoxib in the treatment of ER positive postmenopausal early breast cancer:**
   Steering Committee member & Translational Science co-ordinator.
8. **OPTIMA Trial**: Use of prognostic markers to identify patients for whom optimal therapy is early endocrine treatment, without chemotherapy. Trial Development and Management committee.
9. **ROSCO** – Neoadjuvant targeting of chemotherapy using molecular markers of DNA repair: Trial development and Management committee (in preparation).

***Selected Peer-Reviewed Publications:***

1. Kirkegaard T, McGlynn LM, Campbell FM, Muller S, Tovey SM, Dunne B et al. Amplified in breast cancer 1 in human epidermal growth factor receptor-positive tumors of tamoxifen-treated breast cancer patients. *Clinical Cancer Research* 2007;13:1405-11

2. Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, O'Reilly S et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. *Lancet* 2009;373:1681-92
3. Sauter G, Lee J, Bartlett JMS, Slamon DJ, Press MF. Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations. *Journal of Clinical Oncology* 2009;27:1323-33
4. Bartlett JM, Brookes CL, Robson T, van de Velde CJ, Billingham LJ, Campbell FM, Grant M, Hasenburg A, Hille ET, Kay C, Kieback DG, Putter H, Markopoulos C, Kranenbarg EM, Mallon EA, Dirix L, Seynaeve C, Rea D. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. J Clin Oncol Apr 2011;29(12):1531-8
5. Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H, O'Malley FP, Cardoso F, Tanner M, Munro A, Twelves CJ, Sotiriou C, Shepherd L, Cameron D, Piccart MJ, Buyse M; HER2/TOP2A Meta-analysis Study Group. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. *Lancet Oncol* Nov 2011;12(12):1134-42
6. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF, International Ki-67 in Breast Cancer Working Group. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. *J Natl Cancer Inst*. Nov 2011;103(22):1656-64
7. Pritchard KI, Munro A, O'Malley FP, Tu D, Li X, Levine MN, Shepherd L, Chia S, Bartlett JM. Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial. *Breast Cancer Res Treat* Jan 2012;131(2):541-51
8. Spears M, Pederson HC, Lyttle N, Gray C, Quintayo MA, Brogan L, J Thomas JS, Kerr GR, Jack WJ, Kunkler IH, Cameron DA, Chetty U, Bartlett JM. Expression of activated type I receptor tyrosine kinases in early breast cancer. *Breast Cancer Res Treat* July 2012;134(2):701-8
9. Spears M, Cunningham CA, Taylor KJ, Mallon EA, Thomas JS, Kerr GR, Jack WJ, Kunkler IH, Cameron DA, Chetty U, Bartlett JM. Proximity ligation assays for isoform-specific Akt activation in breast cancer identify activated Akt1 as a driver of progression. *J Pathol* Aug 2012;227(4):481-9
10. Bartlett JMS, Bloom KJ, Piper T, Lawton TJ, van de Velde CJH, Ross DT, Seitz RS, Beck RA, Hasenburg A, Kieback D, Putter H, Markopoulos C, Dirix L, Seynaeve C, Rea D. Mammostrat as an Immunohistochemical Multigene Assay for Prediction of Early Relapse Risk in the TEAM Pathology Study. *J Clin Oncol* (October 2012 – Epub ahead of print)

***Research Funding (Currently Held):***

- 2012-2013 Breast Cancer Research Foundation: Cardoso F (PI), Giordano SH, Porter PL, **Bartlett JMS** (co-PI). Male Breast Cancer: Understanding the Biology for Improved Patient Care: An International Program Coordinated by European Organisation for Research and Treatment of Cancer (EORTC), Translational Breast Cancer Research Consortium (TBCRC), The Breast International Group (BIG) & The North American Breast Cancer Groups (NABCG) (US$240,000) (October 2012 – September 2013
- 2011-2013 NHS National Institute for Health Research - Health Technology Assessment: Stein R (PI), **Bartlett JMS** (co-I), et al. OPTIMA prelim: Optimal Personalised Treatment of breast cancer using Multi-parameter Analysis: preliminary study (GBP 1,974,203)
- 2011-2013 Medical Research Council Strategic Grant: Robson T (PI), Gallagher W, McCarthy H, **Bartlett J** (co-I). A novel prognostic and predictive marker of resistance to endocrine therapies (GBP410,008) (Proposed start date: February 2011
- 2006-2013 Pfizer (UK) – REACT: Randomised European Adjuvant Celecoxib Trial: **Bartlett JMS** (PI) et al. TRANS-REACT (approx. C$265,150)
- 2005-2014 Medical Research Council (UK) – MRC G0400170: Kunkler I (PI), **Bartlett JMS** (co-I), et al. SUPREMO Randomised Trial of Post Operative Radiotherapy: PI for Translational Studies (approx. C$4,700,000)

***Expertise Key Words:***

Pathology, Oncology, Diagnostics, Biochemistry, Biobanking